Leigh Disease clinical trials
The registry lists 20 studies for Leigh Disease across more than 10 countries. 9 are recruiting or about to start. 11 of them are mainly about Leigh Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.
Get an email when these change. Save the Leigh Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
PTC Therapeutics (5) · Khondrion BV (2) · Amgen (2) · Columbia University (2) · LMU Klinikum (1) · Aadi Bioscience, Inc. (1) · Matthew Demczko (1) · Thiogenesis Therapeutics, Inc. (1)
What is being tested here
Drugs under test in Leigh Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Tissue Sample Study for Mitochondrial Disorders · Columbia University
- Dec 2026North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) · Columbia University
- Jun 2027A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS) · Thiogenesis Therapeutics, Inc.
Who these studies take
Of the 6 Leigh Disease studies recruiting now, 4 (67%) set no upper age limit and 0 (0%) stop at 75 or younger. 6 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (33%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 6 (100%) | 6 (100%) |
| 18 | 6 (100%) | 6 (100%) |
| 30 | 6 (100%) | 6 (100%) |
| 40 | 6 (100%) | 6 (100%) |
| 50 | 6 (100%) | 6 (100%) |
| 65 | 6 (100%) | 6 (100%) |
| 75 | 6 (100%) | 6 (100%) |
| 85 | 6 (100%) | 6 (100%) |
Across all 20 studies, recruiting or not: 55% stop at 75 or younger and 55% at 65; 95% take children; 0% are for women only and 5% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of MetabolismRecruitingNCT017801681 country
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931681 country
- Global Registry and Natural History Study for Mitochondrial DisordersRecruitingNCT055548353 countries
- A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)Not yet recruitingNCT06990984Phase 2
- Sirolimus for Leigh SyndromeEnrolling by invitationNCT06843811Phase 21 country
- North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)RecruitingNCT016949402 countries
- Tissue Sample Study for Mitochondrial DisordersEnrolling by invitationNCT018039061 country
- Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural CellsRecruitingNCT069678311 country
- The International Registry for Leigh SyndromeRecruitingNCT031373551 country
- A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyTerminatedNCT04378075Phase 2/39 countries
- A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseaseCompletedNCT05218655Phase 37 countries
- The KHENERGYC StudySuspendedNCT04846036Phase 21 country
- Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial DiseaseCompletedNCT02023866Phase 21 country
- A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial DiseaseTerminatedNCT02473445Phase 21 country
- Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh SyndromeCompletedNCT02352896Phase 21 country
- EPI-743 for Mitochondrial Respiratory Chain DiseasesNo longer availableNCT013704471 country
- A Study of the Natural Course of SURF1 DeficiencyWithdrawnNCT052773631 country
- ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like SyndromeWithdrawnNCT03747328Phase 2
- A Dose-escalating Clinical Trial With KH176CompletedNCT02544217Phase 11 country
- Safety and Efficacy Study of EPI-743 in Children With Leigh SyndromeCompletedNCT01721733Phase 21 country